Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKTX NASDAQ:CVKD NASDAQ:DARE NASDAQ:PPBT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKTXAkari Therapeutics$1.02-2.9%$0.91$0.57▼$3.15$34.24M0.36468,943 shs66,942 shsCVKDCadrenal Therapeutics$13.96+2.6%$12.77$8.74▼$22.90$27.87M0.9628,879 shs20,027 shsDAREDare Bioscience$2.29+2.2%$2.12$1.83▼$9.19$30.26M1.14128,335 shs141,249 shsPPBTPurple Biotech$0.58-0.9%$1.37$0.53▼$13.95$7.46M0.61372,513 shs160,887 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKTXAkari Therapeutics-2.86%+4.06%+20.00%-10.92%-66.23%CVKDCadrenal Therapeutics+2.57%-0.71%+4.41%+7.38%+12.76%DAREDare Bioscience+2.23%+6.51%+7.51%-4.18%-29.75%PPBTPurple Biotech-0.93%-1.81%-3.94%-77.52%-86.07%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKTXAkari Therapeutics$1.02-2.9%$0.91$0.57▼$3.15$34.24M0.36468,943 shs66,942 shsCVKDCadrenal Therapeutics$13.96+2.6%$12.77$8.74▼$22.90$27.87M0.9628,879 shs20,027 shsDAREDare Bioscience$2.29+2.2%$2.12$1.83▼$9.19$30.26M1.14128,335 shs141,249 shsPPBTPurple Biotech$0.58-0.9%$1.37$0.53▼$13.95$7.46M0.61372,513 shs160,887 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKTXAkari Therapeutics-2.86%+4.06%+20.00%-10.92%-66.23%CVKDCadrenal Therapeutics+2.57%-0.71%+4.41%+7.38%+12.76%DAREDare Bioscience+2.23%+6.51%+7.51%-4.18%-29.75%PPBTPurple Biotech-0.93%-1.81%-3.94%-77.52%-86.07%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKTXAkari Therapeutics 2.33Hold$3.30223.53% UpsideCVKDCadrenal Therapeutics 2.00Hold$32.00129.23% UpsideDAREDare Bioscience 2.33Hold$10.00336.68% UpsidePPBTPurple Biotech 2.00Hold$33.005,635.14% UpsideCurrent Analyst Ratings BreakdownLatest PPBT, AKTX, DARE, and CVKD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025AKTXAkari TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025CVKDCadrenal TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025DAREDare BioscienceWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025PPBTPurple BiotechWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025AKTXAkari TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025CVKDCadrenal TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025DAREDare BioscienceWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025PPBTPurple BiotechWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/9/2025AKTXAkari TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$1.609/4/2025DAREDare BioscienceMaxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$8.007/18/2025AKTXAkari TherapeuticsMaxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$5.00(Data available from 10/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKTXAkari TherapeuticsN/AN/AN/AN/A$0.84 per shareN/ACVKDCadrenal TherapeuticsN/AN/AN/AN/A$4.17 per shareN/ADAREDare Bioscience$10K3,086.92N/AN/A($0.69) per share-3.32PPBTPurple BiotechN/AN/AN/AN/A$12.73 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKTXAkari Therapeutics-$19.79MN/A0.00∞N/AN/A-78.03%-31.62%11/18/2025 (Estimated)CVKDCadrenal Therapeutics-$10.65M-$8.88N/AN/AN/AN/A-265.37%-196.38%11/6/2025 (Estimated)DAREDare Bioscience-$4.05M-$2.14N/AN/AN/AN/AN/A-103.70%11/13/2025 (Estimated)PPBTPurple Biotech-$7.24M-$0.42N/AN/AN/AN/A-14.00%-12.52%11/21/2025 (Estimated)Latest PPBT, AKTX, DARE, and CVKD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025DAREDare Bioscience-$0.55-$0.45+$0.10-$0.45$0.14 million($0.02) million8/11/2025Q2 2025CVKDCadrenal Therapeutics-$1.60-$1.87-$0.27-$1.87N/AN/A8/6/2025Q2 2025PPBTPurple Biotech-$0.21-$0.40-$0.19-$0.40N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKTXAkari TherapeuticsN/AN/AN/AN/AN/ACVKDCadrenal TherapeuticsN/AN/AN/AN/AN/ADAREDare BioscienceN/AN/AN/AN/AN/APPBTPurple BiotechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKTXAkari TherapeuticsN/A0.190.19CVKDCadrenal TherapeuticsN/A3.553.55DAREDare BioscienceN/A0.340.34PPBTPurple BiotechN/A2.882.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKTXAkari Therapeutics5.06%CVKDCadrenal Therapeutics7.92%DAREDare Bioscience6.70%PPBTPurple Biotech9.64%Insider OwnershipCompanyInsider OwnershipAKTXAkari Therapeutics38.10%CVKDCadrenal Therapeutics26.09%DAREDare Bioscience4.80%PPBTPurple Biotech2.98%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKTXAkari Therapeutics932.62 million20.19 millionNot OptionableCVKDCadrenal Therapeutics42.05 million1.51 millionNot OptionableDAREDare Bioscience3013.48 million12.83 millionNot OptionablePPBTPurple Biotech2012.85 million12.46 millionOptionablePPBT, AKTX, DARE, and CVKD HeadlinesRecent News About These CompaniesPurple Biotech Unveils Promising Cancer Treatment Developments in September 2025 UpdateSeptember 16, 2025 | msn.comPurple Biotech receives intention to grant a European patent covering NT219September 10, 2025 | msn.comPurple Biotech Receives Intention to Grant a European Patent Covering NT219 Combinations with Immunotherapies or MEK Inhibitors to Overcome Tumor ResistanceSeptember 10, 2025 | finance.yahoo.comPurple Biotech Announces Closing of Up To $18 Million Public Offering $6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the ...September 6, 2025 | markets.businessinsider.comPurple Biotech Announces Closing of Up To $18 Million Public Offering $6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of short-term warrantsSeptember 5, 2025 | globenewswire.comPurple Biotech prices 5.99M ADSs at $1.00 in public offeringSeptember 4, 2025 | msn.comPurple Biotech Announces Pricing of Up To $18 Million Public OfferingSeptember 4, 2025 | markets.businessinsider.comPurple Biotech Announces New Data Supporting the Unique Design of CAPTN-3 Tri-Specific Antibody IM1240 in Collaboration with the Icahn School of Medicine at Mount SinaiSeptember 4, 2025 | markets.businessinsider.comPurple Biotech Expands CAPTN-3 Portfolio with Novel Antibody Targeting TROP2September 3, 2025 | msn.comPurple Biotech Expands CAPTN-3 Portfolio with IM1305, a Novel Tri-Specific Antibody Targeting TROP2September 3, 2025 | markets.businessinsider.comPurple Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment ConferenceAugust 27, 2025 | globenewswire.comPurple Biotech Reports Second Quarter 2025 Financial ResultsAugust 6, 2025 | globenewswire.comPurple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025July 23, 2025 | globenewswire.comPurple Biotech Stock Price History - Investing.comJuly 8, 2025 | investing.comPurple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual CongressJune 23, 2025 | globenewswire.comPurple Biotech Announces Initiation of Phase 2 Study of NT219 in Patients with Head and Neck CancerJune 17, 2025 | finance.yahoo.comPurple Biotech Announces Poster Presentation at EACR 2025 on its Novel CAPTN-3 Tri-Specific Antibody PlatformJune 4, 2025 | finance.yahoo.comH.C. Wainwright Raises Purple Biotech (PPBT) Price Target, Reiterates Buy RatingJune 1, 2025 | msn.comPurple Biotech Ltd.: Purple Biotech Reports First Quarter 2025 Financial ResultsMay 21, 2025 | finanznachrichten.dePurple Biotech Reports First Quarter 2025 Financial ResultsMay 21, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePPBT, AKTX, DARE, and CVKD Company DescriptionsAkari Therapeutics NASDAQ:AKTX$1.02 -0.03 (-2.86%) Closing price 10/8/2025 03:59 PM EasternExtended Trading$1.02 0.00 (0.00%) As of 10/8/2025 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.Cadrenal Therapeutics NASDAQ:CVKD$13.96 +0.35 (+2.57%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$13.93 -0.03 (-0.21%) As of 10/8/2025 04:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.Dare Bioscience NASDAQ:DARE$2.29 +0.05 (+2.23%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$2.30 +0.00 (+0.22%) As of 10/8/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.Purple Biotech NASDAQ:PPBT$0.58 -0.01 (-0.93%) Closing price 10/8/2025 03:59 PM EasternExtended Trading$0.58 +0.00 (+0.28%) As of 10/8/2025 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Archer Aviation Stock Is Soaring—And What Comes Next Lithium Americas: Why This 31% Rally Is More Than Just a Headline Energy Transfer's New Growth Engine Ignites Investor Interest AMD Could Double From Here—Thanks to Its Blockbuster OpenAI Deal AMD and OpenAI: A Partnership That Just Redrew the AI Map EA’s $55 Billion Deal Spurs a Shake-Up in the Gaming Sector 3 Dividend Aristocrats to Buy Before Year’s End Falcon Flex Drives Growth as CrowdStrike Bets on AI Security Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
